ALACHUA, Fla., June 13 /PRNewswire-FirstCall/ -- Oragenics, Inc. (Amex: ONI - News) announced today its plans to initiate a human study for its proprietary oral probiotic product, Probiora3(TM). Subject recruitment will begin within a month. The study is designed to determine the effects of the mouthrinse on oral health, and will involve twenty subjects who will use the Probiora3(TM) mouthrinse twice daily for one to two months.
